Imatinib treatment of lymphangiomatosis (generalized lymphatic anomaly) Academic Article Article uri icon

Overview

MeSH Major

  • Anterior Cruciate Ligament Injuries
  • Anterior Cruciate Ligament Reconstruction
  • Athletic Injuries
  • Knee Injuries

abstract

  • Lymphangiomatosis (eg, generalized lymphatic anomaly) is an abnormal proliferation of lymphatic endothelial cells. It is often a childhood disease, but it may present in adulthood by infiltrating organs and cause obstruction, bleeding, or disruption of lymphatic flow. Pulmonary involvement may be mild or cause diffuse interstitial lung disease, airway obstruction, hemoptysis, chylothorax, chylopericardium, and culminate in respiratory failure. Treatment has been limited to surgical resection or drainage procedures because there is no accepted effective systemic therapy. This report presents a patient with lymphangiomatosis and life-threatening hemoptysis in whom positive immunostaining forc-KITsuggested upregulation of tyrosine kinase and whose disease was controlled with imatinib.

publication date

  • April 2016

Research

keywords

  • Academic Article

Identity

PubMed ID

  • 27059187

Additional Document Info

start page

  • 383

end page

  • 6

volume

  • 14

number

  • 4